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Abstract 1 
Periods of fasting and refeeding may reduce cardiometabolic risk elevated by Western diet. We 2 
show that in hypertensive metabolic syndrome (MetS) patients (n=35), a 5-day fast followed 3 
by a modified DASH diet (Dietary Approach to Stop Hypertension) reduced systolic blood 4 
pressure (SBP), antihypertensive medication need, and body-mass index (BMI) at three months 5 
post intervention compared to a modified DASH diet alone (n=36). Fasting altered the gut 6 
microbiome, impacting bacterial taxa and gene modules associated with short-chain fatty acid 7 
production. Cross-system analyses revealed a positive correlation of circulating mucosa-8 
associated invariant T (MAIT) cells, non-classical monocytes and CD4+ effector T cells with 9 
SBP. Furthermore, regulatory T cells (Tregs) positively correlated with BMI and weight. 10 
Machine learning could predict sustained SBP-responsiveness within the fasting group from 11 
baseline immunome data, identifying CD8+ effector T cells, Th17 cells and Tregs as important 12 
contributors to the model. The high-resolution multi-omics data highlights fasting as a 13 
promising non-pharmacological intervention in MetS. 14 
Keywords 15 
metabolic syndrome, hypertension, periodic fasting, microbiome, immunome 16 
 17 
Fasting can prolong survival and reduce disease burden in rodent models, and possibly in 18 
humans1. In contrast, today’s Western diet promotes cardiometabolic disease2. The relationship 19 
how diet affects the gut microbiota, immune system and subsequently host (patho)physiology 20 
is not fully understood, and information is lacking on how periodic fasting affects the gut 21 
microbiome in patients with metabolic syndrome (MetS). To reduce cardiometabolic disease 22 
(CMD) risk, exercise and a healthy diet are often prescribed. Shifting from a ‘Western diet’ to 23 
a healthier ‘Mediterranean-like’ DASH diet3 to achieve optimal nutrition and negative energy 24 
balance is recommended, although compliance is a major hurdle. Our study is the first of its 25 
kind to investigate the effects of a lifestyle modification in combination with fasting therapy in 26 
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patients with MetS using a multi-omics approach. The ‘Western diet’ is known to induce 1 
metabolic inflammation, accelerating CMD4. The gut microbiota is a delicate ecosystem that 2 
plays a pivotal role in health and disease. Dysbiosis has been observed as a characteristic of 3 
several inflammatory, cardiovascular, and metabolic disorders (e.g. obesity)5, including 4 
hypertension6, 7. The ‘healthy’ gut microbiome is relatively stable, although various factors such 5 
as antibiotics, intestinal infections, profound dietary or lifestyle changes, such as moving on or 6 
off a ‘Western diet’ can induce transient or persistent changes to this ecosystem. Traditionally, 7 
fasting plays an important role in different cultural and religious practices. Dramatic caloric 8 
restriction not only affects host health and physiology, but likely also has an impact on the 9 
microbiome. However, the effect of fasting on the gut microbiome and the consequences of 10 
refeeding after such an intervention have not yet been described. 11 
 12 
Methods 13 
Study design and patients 14 
Subjects diagnosed with MetS and elevated systolic blood pressure (BP) were randomly 15 
allocated into two intervention groups. The fasting arm underwent five days of fasting 16 
according to ‘Buchinger´s protocol’8 followed by three months of a modified DASH diet (also 17 
referred to as the refeeding period) (Figure 1A, Table 1). The other arm underwent a modified 18 
DASH intervention only (referred to as DASH). Ethical approval was obtained from the local 19 
ethics committee (No. EA4/141/13). Informed consent was obtained from all subjects before 20 
entering the study. The present study complies with the Declaration of Helsinki and was 21 
registered at ClinicalTrials.gov (NCT02099968). For further methodological and statistical 22 
details, see Supplementary information online. 23 
 24 
  25 
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Results 1 
Fasting affects the gut microbiome and immunome 2 
As we have previously reported a major influence of common MetS drugs on the microbiota9, 3 
we accounted for any changes in medication regime or dosage in our statistical tests, alongside 4 
controlling for important demographic features such as age and sex. Neither fasting nor 5 
refeeding significantly (Mann-Whitney U (MWU) P>0.05) altered microbiome species 6 
richness/alpha diversity (Shannon, Figure 1B, Supplementary Figure S1), or intersample gut 7 
taxonomic variability/beta diversity (intersample Bray-Curtis distance, Figure 1C; similar 8 
results achieved on 16S data (results not shown)). However, there were substantial and 9 
significant (PERMANOVA P=0.001) differences in microbial composition within individuals 10 
during fasting, reflecting a characteristic intervention-induced shift, which later partially 11 
reverted upon a three-month refeeding on a DASH diet (Figure 1D, Supplementary Table S1 12 
and Figure S2A). This was echoed by analogous significant (PERMANOVA P=0.001) changes 13 
in host immune cell composition during the intervention, revealing a fasting-specific signature, 14 
which likewise largely reversed during refeeding (Figure 1E, Supplementary, Table S1). DASH 15 
without fasting neither affected the microbial composition nor the host immune cell 16 
composition (P=0.72 and P=0.38, respectively Supplementary Figure S2B-C).  17 
Fasting resulted in a reduction of CD3+, CD4+ T cells and CD19+ B cells, while the frequency 18 
of CD8+ T cells was unaltered. In contrast, fasting increased the abundance of monocytes 19 
(CD14+CD11c+CD19-CD3-) and TCR+ T cells. However, these changes were reversed upon 20 
refeeding (Figure 1H, Supplementary Table S2). Of note, frequency of CD123+CD14-CD16-21 
HLA-DR+ plasmacytoid dendritic cells also increased upon fasting and was still enriched after 22 
refeeding (Figure 1H, Supplementary Table S2). When looking closer into monocyte subsets, 23 
fasting increased (and refeeding reduced) the frequency of classical CD14highCD16-, non-24 
classical CD14lowCD16++, and intermediate CD14highCD16+ monocytes (Figure 1I, 25 
Supplementary Figure S3, Table S2), which was confirmed by unbiased FlowSOM analyses 26 
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(Supplementary Figure S4A-D). Fasting also affected the relative abundance of differentially 1 
activated T cells. Upon fasting, CD8+ T cells showed a higher percentage of terminally 2 
differentiated cells (Teff, CD45RO
-CD62L-) and a lower percentage of the naïve phenotype (Tn, 3 
CD45RO-CD62L+), while memory T cells were not affected (Figure 1I, Supplementary Figure 4 
S3, Table S1). A similar pattern was observed in CD4+ Teff (Figure 1I, Supplementary Table 5 
S1). Further, fasting decreased the frequency of pro-inflammatory Th17 (CD27bright 6 
CD161+CCR6+CXCR3-CD25-CD4+), as well as TNF- and IFN-producing Th1 cells (Figure 7 
1I, Supplementary Table S1). These changes were partially reverted upon refeeding (Figure 1I). 8 
Neither fasting nor refeeding changed the overall frequency of CD161+V7.2+ CD3+ mucosa-9 
associated invariant cells (MAIT, Figure 1H, Supplementary Figure S3). However, frequency 10 
of pro-inflammatory MAITs producing TNF and IFN significantly decreased upon fasting 11 
and were minimally affected by refeeding (Figure 1I, Supplementary Table S2). 12 
Next, we tested all gut microbial taxa and gene functional (KEGG10, GMM11) modules for 13 
abundance shifts during fasting or refeeding, as well as persistent shifts across the three-month 14 
study period, controlling for age, sex and any changes in medication (Figure 1F-H, 15 
Supplementary Table S1). Fasting stimulated shifts in abundance of several core commensals, 16 
which was reversed upon refeeding (Figure 1F, Supplementary Table S1). Many Clostridial 17 
Firmicutes shifted significantly in abundance, with an initial decrease in butyrate producers 18 
such as F. prausnitzii, E. rectale and C. comes, which had also reverted after three months. 19 
Interestingly, C. comes abundance change was predominantly driven by changes in BMI. 20 
Bacteroidaceae showed the opposite pattern and an OTU identified as an Odoribacter species 21 
likewise bloomed during fasting. At the end of the refeeding period, a persistent depletion could 22 
be seen in Enterobacteriaceae, especially Escherichia coli. Accompanying the shift in 23 
composition are vast changes in microbial metabolic capacity (Figure 1G, Supplementary Table 24 
S1). Fasting enriches for propionate production capacity, mucin degradation gene modules and 25 
for diverse nutrient utilization pathways. 26 
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Reanalyzing previously published data, we compared the microbiome signatures of metformin 1 
use and MetS to those seen in our novel dataset9, 12. For ease of comparability, we proceeded 2 
with only human gut specific functional modules (GMM) assessed from shotgun sequencing 3 
data available for the fasting arm. Certain fasting- or refeeding-associated functional gene 4 
modules from our data were found to overlap with signatures of metformin usage or MetS, but 5 
there was little concordance on a taxonomic composition level, in line with previously described 6 
higher functional than taxonomic concordance between microbiomes. Of note, when comparing 7 
the metformin signal to the MetS signal, it is clear that these two effects are functionally distinct 8 
and often oppose one another. Where there were overlapping functional features with results 9 
from our novel cohort, the fasting effect appeared to be metformin-like, and during recovery 10 
metabolic changes were again reverted (Supplementary Figure S5). That is, certain gut 11 
metabolic capacities are promoted both by fasting and by metformin treatment.  12 
 13 
Fasting reduces long-term systolic blood pressure and body weight in MetS patients  14 
Assessing the clinical relevance of our intervention, we inspected clinical outcomes in the two 15 
study arms. While DASH reduced office SBP after three months (Figure 2H), it did not 16 
significantly (MWU P=0.27) affect 24h ambulatory SBP, the gold standard of clinical BP 17 
measurements (Figure 2A)3. In contrast, fasting followed by a modified DASH diet led to a 18 
sustained reduction both in 24h ambulatory SBP and mean arterial pressure (MAP) (MWU 19 
P<0.05, Figure 2A). Further, subjects undergoing fasting could significantly (2 P=0.035) 20 
reduce their intake of antihypertensive medication in 43% of cases, compared to only 17% of 21 
the cases on DASH alone, while their BP remained under control (Figure 2B, Supplementary 22 
Table S2). Because the BP response to fasting was heterogenous in our cohort (Figure 2A-B), 23 
we applied a decision tree model to stratify patients based on their ambulatory BP response, 24 
adjusted for antihypertensive medication (Supplementary Figure S6, Table S3). The responder 25 
group had a median SBP decrease of 8.0 mmHg including a high reduction of medication, while 26 
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the decrease in the non-responder group was significantly lower (0.3 mmHg; Figure 2C). In the 1 
DASH only arm, 17 patients were classified as responders with a median SBP decrease of 8.0 2 
mmHg, while the non-responders (n=14) showed no decrease in median SBP (0.5 mmHg, 3 
Figure 2C). Fasting followed by a modified DASH diet, unlike a modified DASH diet alone, 4 
significantly (drug-adjusted post hoc P<0.05) reduced BMI and body weight even three months 5 
post-fasting (Figure 2D-E). Although all participants showed a reduction in body weight, this 6 
reduction alone could not explain the long-term ambulatory SBP and MAP changes exclusive 7 
to the fasting arm (Figure 2F-G), nor the microbiome or immunome changes accompanying it 8 
(95% of significant findings retain significance when BMI is added as a predictor to the nested 9 
models for longitudinal data, see Supplementary Table S4). Only a minority of significant 10 
effects (and only two microbiome effects) observed in the fasting-DASH arm could be 11 
replicated in the equally powered DASH-only arm (Figure 2I). 12 
 13 
BP responder-specific changes in the gut microbiome and immunome  14 
Because the BP responsiveness was heterogenous in the fasting-DASH arm (Figure 2A-C), we 15 
hypothesized that unique characteristics involving the immunome or microbiome of these 16 
patients may contribute to their BP response. We compared the impact of fasting and refeeding 17 
in the complete fasting arm, in the BP-responders of the fasting arm, and in the DASH-only 18 
arm (Figure 3A-B, Supplementary Table S1, 5, 6). Even at reduced statistical power, we were 19 
able to capture changes in abundance of many gut microbial taxa that were uniquely 20 
characteristic of successful fasting treatment, most of which displayed the fasting-refeeding 21 
reversal dynamic described above (Figure 3A, Supplementary Table S5, 6). Responders were 22 
especially characterized by an initial and sustained enrichment of an unclassified Odoribacter 23 
species with concomitant Actinomyces depletion. Responders experienced an initial depletion, 24 
and later a strong enrichment, of the butyrate producer F. prausnitzii. Accordingly, in BP-25 
responders, fasting resulted in an initial bloom and later depletion of Bacteroides (Figure 3A). 26 
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Virtually no overlap with effects seen in the equally powered DASH arm were found, indicating 1 
that fasting is needed on top of a BP-reducing diet for these changes to occur (Supplementary 2 
Figure S7). 3 
In profiling the microbial metabolic potential in BP-responders, we focused on gene modules 4 
curated for relevance to metabolism in the human gut (GMM)11. On a functional level, 5 
responder-characteristic changes resemble those in the fasting arm at large, but with even more 6 
pronounced relative enrichment for propionate production (MF0126, MF0121) modules 7 
(Figure 3B). Some modules were significantly altered in abundance only in this stratified 8 
subgroup, indicating these changes strongly characterize responders compared to non-9 
responders (Supplementary Table S5). For example, pyruvate:formate lyase (MF0085) is 10 
depleted during recovery only in responders.  11 
Changes to the immunome of responders are similar to those seen in the unstratified fasting 12 
group and differ from those in the DASH arm (Figure 3C, Supplementary Table S1, 5, 6). In 13 
the fasting arm, several immune features related to pathogen-sensing and mucosal immunity 14 
(e.g. MAIT cells, IL-17+-producing Th and T cells) changed significantly in abundance only 15 
when tested in the responder group, indicating relevant differences between responders and 16 
non-responders. Upon fasting, frequency of both pro- and anti-inflammatory adaptive immune 17 
cells showed a stronger decrease in responders, indicating a stronger anti-inflammatory effect 18 
of fasting in responders.  19 
 20 
Network analysis of microbial, immune, and clinical features 21 
We next aimed to study interacting microbiome-immune features through network analysis, 22 
seeking to explain the beneficial role of fasting on BP. We assessed all triplets of pairwise 23 
interactions between host clinical phenotypes, immune cell populations, and microbiome taxa 24 
or functional profiles, respectively, using modified Spearman correlations (requiring FDR<0.1 25 
in each comparison of two data spaces, and P<0.05 in a post hoc test accounting for the presence 26 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted February 25, 2020. .https://doi.org/10.1101/2020.02.23.20027029doi: medRxiv preprint 
10 
of the same subjects at all three time points (see Methods, Supplementary Table S7). Figure 4A 1 
shows a chord diagram constructed from these data, where the colored outer rings are lined with 2 
components from one of our three tested system spaces during fasting, refeeding and over the 3 
full duration of the study, and where the color of the connectors between factors indicate a 4 
positive or negative association (Spearman´s rho).  We identified a cluster of circulating 5 
cytokine-producing MAIT cells (absolute number and fraction of CD3+ T cells), which 6 
positively correlated with 24h ambulatory SBP (Figure 4A, E, Supplementary S8) and MAP, 7 
but not with 24h diastolic BP (Figure 4A, Supplementary Table S7). In our patients, a number 8 
of IL-2+TNF+ producing-MAIT cells positively correlated with the abundance of a species of 9 
Firmicutes (unclassified) [meta_mOTU v2 6331] and negatively with Bifidobacteriales (Order-10 
16S), while IFN+ producing-MAIT cells positively correlated with abundance of Barnesiella 11 
intestinihominis [ref_mOTU v2 4880], Clostridiales sp. (unclassified) [meta_mOTU v2 6787] 12 
and Bacteroides eggerthii [ref_mOTU v2 1410] (Figure 4A, D, Supplementary Table S9). 13 
Abundance of various microbes including Coprococcus sp. were negatively associated with 14 
IFN+ producing-MAIT cells (Figure 4A, D, Supplementary Table S9). Interestingly, fasting 15 
depleted various cytokine producing-MAIT cells with the most pronounced long-lasting 16 
decrease seen for IL-2+TNF+ producing-MAIT in BP-responders (Figure 4A-C, 17 
Supplementary Table S9).  18 
The association between MAIT cells and BMI is still a matter of debate13. We found in our 19 
study that the abundance of MAIT cells did not correlate with either BMI, weight, waist 20 
circumference, waist-hip ratio or body fat percentage (Supplementary Figure S8, Table S7). 21 
However, we found that these weight-related parameters did correlate with the abundance of a 22 
subset of circulating Treg-like cells (CD62L-CD45RO-CD25+CD4+), a cell type previously 23 
linked to morbid obesity in human subjects14. 24 
A recent publication showed non-classical monocyte enrichment in hypertensive patients15. 25 
Interestingly in our study, circulating non-classical monocytes were enriched upon fasting and 26 
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then depleted again upon refeeding to remain below baseline levels three months after fasting 1 
(Figure 1H, 4A, Supplementary Table S1). Network analysis revealed an association between 2 
non-classical monocytes, MAP and gut abundance of Betaproteobacteria. Sutterella spp., 3 
belonging to the class Betaproteobacteria, showed an inverse correlation with non-classical 4 
monocytes, while Clostridiales [meta_mOTU_v2_6233] was positively associated with non-5 
classical monocytes and MAP (Figure 4A, D, F, Supplementary Table S7). We found that the 6 
frequency of circulating GM-CSF-producing CD4+ T cells was negatively correlated with 7 
unclassified Firmicutes [meta_mOTU v2 7454] and Clostridiales sp. (unclassified) 8 
[meta_mOTU v2 5411], and positively with SBP (Figure 4A, D, G, Supplementary Table S7).  9 
 10 
Baseline indicators predicting efficacy of fasting on blood pressure 11 
As previously stated, a large proportion of fasting patients responded with a substantial drop in 12 
BP, allowing them to reduce their use of anti-hypertensive medication while BP remained 13 
controlled. As not all patients experienced this beneficial effect, we sought to understand 14 
whether the factors underlying successful fasting intervention in the BP-responders could be 15 
predicted at baseline. Responder and non-responder subgroups differ considerably in 16 
immunome and microbiome features, not only post-fasting and at three-month follow-up, but 17 
also at baseline, suggesting a favorable clinical response may be predictable in single patients 18 
(Supplementary Figure S9A-C). Regarding responder-specific features, we identified a small 19 
number of features as both characteristic of responders at baseline and during the intervention 20 
(Figure 5A). Microbiomes of BP responders were depleted pre-intervention for two poorly 21 
characterized taxa (Bacteroides sp. and Parabacteroides sp.) and for propionate biosynthesis 22 
(Figure 5A). Fasting strongly elevated the abundance of both taxa and enriched these propionate 23 
production modules, indicating that responders suffer a treatable deficit. By three months post 24 
intervention, propionate modules and Bacteroides sp. are almost back at baseline while BP 25 
(relative to medication dosage) remains improved, suggesting that their transient elevation 26 
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during refeeding may have stabilized a less hypertensive state through downstream 1 
mechanisms. In addition, the difference in abundance of Parabacteroides sp. in responders and 2 
non-responders had equalized by time of follow-up.  3 
As mentioned above, immunome composition also differed already at baseline in responders 4 
and non-responders. To further elucidate this phenomenon, we applied machine learning 5 
algorithms and empirically show that we can make effective predictions from the immunome 6 
data. From 494 total immune variables, step-wise forward regression identified the top ten 7 
discriminators of responders from non-responders at baseline. A prediction accuracy of 71% 8 
(sensitivity 75%, specificity 70%, and F1 score 77%) was achieved using a leave-subject-out 9 
cross-validation for whether or not a future patient would respond favorably to fasting with 10 
regards to BP (Figure 5B). Within this multivariate analysis, the driving immune features of 11 
this classifier highlighted a lower CXCR3+CD25–CD4+/CD25highCD4+ (most likely Th1/Treg 12 
ratio), alongside lower abundances of CD24+ memory CD8+ T cells and IL-17+TNF+MAIT 13 
cells in responders relative to non-responders (Figure 5C, Supplementary Figure S9E). 14 
Regarding the top ten features derived as indicative for successful patient classification, 15 
responders seem to have less of a pro-inflammatory immune signature at baseline (Figure 5C). 16 
Notably, we could increase the prediction performance of the classifier up to 78% by using 17 
changes of immune cell abundances between baseline and three-month follow-up visit as a basis 18 
for prediction of BP response at the single-patient level (Supplementary Figure S9D, F). In 19 
contrast, for subjects on a DASH diet only, corresponding classifiers were unable to predict BP 20 
response above chance level.  21 
 22 
Discussion  23 
In summary, we have carried out the first high-resolution multi-omics characterization of 24 
fasting in patients with metabolic syndrome. The major novel finding is that periodic fasting 25 
followed by 3 months of modified DASH diet induces concerted and distinct microbiome and 26 
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immunome changes that are specific to fasting itself leading to a sustained BP benefit (Fig. 2I), 1 
since it cannot be reduced by DASH diet alone. Fasting followed by modified DASH led to a 2 
significant long-term reduction in body weight. However, neither the change in blood pressure 3 
nor global changes to the microbial composition or immunome appear mediated by this BMI 4 
decrease (95% of findings retain significance when deconfounding for BMI change, see Table 5 
S4, and body weight reduction is not more pervasive in treatment responders than 6 
nonresponders, Figure 2G). This suggests that further sustained weight loss beyond what is 7 
observed here may synergize with the fasting benefits to reduce hypertension even further. 8 
Fasting induced a profound change in circulating immune populations; e.g. depleted Th1 cells 9 
and permanently enriched dendritic cells, which both have been shown previously to play a role 10 
in the pathogenesis of experimental hypertension16, 17. Further, we discovered significant 11 
correlations between circulating MAIT cells and 24h ambulatory BP and MAP. 12 
A growing body of evidence suggests that the abundance of certain microbes is associated with 13 
cardiovascular health. Previous reports on hypertensive patients show taxonomic and functional 14 
gut microbiome shifts6, 7. For example, Firmicutes have been shown to be more abundant in 15 
healthy controls compared to pre-hypertensive and hypertensive patients7. Upon fasting, several 16 
Clostridial Firmicutes shifted significantly in abundance, with an initial decrease in butyrate 17 
producers such as F. prausnitzii, E. rectale and C. comes, which were also reverted after three 18 
months upon refeeding; with the latter taxon one of few likely to be indirect effects of the 19 
observed weight reduction (Table S4). Bacteroidaceae showed the opposite pattern, and an 20 
unclassified Odoribacter species likewise bloomed during fasting. Of note, Odoribacter sp. has 21 
been negatively associated with both SBP18 and vascular stiffness19 in obese women. 22 
Escherichia coli was shown to be associated with endothelial dysfunction and MetS. In our 23 
study, fasting permanently depleted Escherichia coli, suggesting that fasting could promote 24 
cardiovascular health through the gut microbiome. Further, functional microbial metabolism in 25 
fasting patients at baseline share some similarities to the previously profiled hypertensive 26 
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microbiome7. In the fasting arm, the functional shift during refeeding enriches for functional 1 
modules also enriched in non-hypertensive controls, i.e. for potentially BP-protective factors. 2 
Clinical studies represent a highly heterogeneous situation with multifactorial disease features 3 
and strongly variable microbial and lived environments. To account for this heterogeneity, we 4 
compared the data from our longitudinal study (post-fasting and 3-month) to the respective 5 
baseline values of the study subjects. This intraindividual analysis allowed us to identify BP 6 
responder-specific changes despite even reduced power in such a sub-stratified analysis. 7 
Notably, despite the non-homogenous starting conditions in our MetS patients, our five-day 8 
fasting followed by a DASH intervention improved BMI in all participants and ambulatory SBP 9 
in two thirds, even three months post-intervention. The responder-specific microbiome changes 10 
in our fasting arm post-intervention (enrichment of an Odoribacter species, Bacteroides and 11 
Firmicutes, depletion of Actinomyces and F. prausnitzii) are likely beneficial to the host.  A 12 
recent study profiling the hypertensive microbiome showed that during disease, patients 13 
experienced an enrichment of Actinomyces, and a depletion of F. prausnitzii, Bacteroides and 14 
Firmicutes7. In addition, some functional gut specific gene modules in our dataset were enriched 15 
only in BP-responders, for example the pyruvate:formate lyase module, MF0085. Our data are 16 
congruent with a study showing enrichment of the same enzyme in symptomatic atherosclerosis 17 
patients compared to healthy controls20. 18 
The fact must also be addressed as to how, despite the fact that many of the immunome and 19 
microbiome shifts post-fasting are transient, there exists a sustained improvement of 20 
cardiovascular health in our patients. We hypothesize that during a specific time window during 21 
early refeeding, certain fasting-depleted taxa (including core butyrate producers) and associated 22 
immune cells may be enriched beyond both baseline or follow-up at 3 month, leading to a 23 
temporary state of high butyrate availability, especially on a DASH diet. Therefore, we 24 
speculate that anti-inflammatory effects of this SCFA during regrowth, as well as similar effects 25 
of propionate during fasting itself, may be important mechanisms behind the sustained 26 
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improvement in blood pressure that we observe. While we cannot directly test it in the present 1 
cohort, it is a scenario consistent both with expectations from the literature and with our 2 
observations of a consistent depletion-then-regrowth pattern. Thus, future work will involve 3 
studying a fasting/refeeding cohort also at intermediate time intervals. It is likewise a limitation 4 
that we cannot infer direction or causality of concomitant immunome-microbiome changes 5 
from the present cohort study alone. Accordingly, our next steps will also involve direct 6 
manipulation of microbiota, as well as direct infusion of their potentially immunomodulating 7 
metabolites, in animal models for hypertension, similar to some of our recent proof-of-principle 8 
studies21, 22.  9 
Stratification of the cohort to BP-responsiveness showed that also immune changes present in 10 
the fasting arm are more pronounced in responders than in non-responders, and are 11 
fundamentally different from the changes observed in the DASH-only arm.  The DASH-only 12 
arm was associated with the decrease of CD8+ Tem cells, previously reported to play a role in 13 
hypertension17, 23. Responders and non-responders not only reacted differentially to fasting, but 14 
also differed at baseline, including by depletion of Bacteroides sp., Parabacteroides sp., and 15 
propionate synthesis genes pre-intervention. These features were then normalized during 16 
fasting. Notably, recent experimental work suggested an anti-hypertensive effect of propionate 17 
treatment in mice.22 Furthermore, Parabacteroides are more commonly found in the 18 
microbiome of hypertensive subjects than in healthy controls6. Our findings indicate responders 19 
and non-responders to our intervention differ with regards to several gut microbiome features 20 
relevant to hypertension, with fasting-induced normalization of these differences seen during a 21 
successful fasting intervention.   22 
Through network analysis of the immunome, microbiome and clinical data, we identified 23 
significant correlations between circulating MAIT cells and 24h ambulatory BP and MAP. 24 
MAIT cells represent up to 10% of peripheral blood T cells, but in contrast to other classical T 25 
cells17, have not yet been linked to the regulation of BP. They differ in many aspects from 26 
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conventional T cells by expressing a semi-invariant TCR -chain V7.2-J33. MAITs can 1 
produce various cytokines mimicking an effector/memory-like phenotype and yet they behave 2 
rather like innate cells. During aging18 and CMD13, 24, absolute circulating MAIT number and 3 
frequencies decrease, while certain subsets of cytokine producing and adipose tissue MAITs 4 
were found to be enriched in obese type 2 diabetic patients13. In contrast to a previous report 5 
showing significant enrichment of IL-17-producing MAIT cells (after re-stimulation) in 6 
severely obese patients (average BMI=5413), our cohort (average BMI=34) had very low IL-17 7 
producing MAITs, and they were only quantifiable in a small group of patients (data not 8 
shown).  9 
Using machine learning, we were able to utilize deep immunophenotyping data to predict at 10 
baseline which subjects were likely to decrease their BP during fasting despite the small number 11 
of subjects. In addition, accuracy of the prediction was enhanced further taking the dynamics 12 
of immune populations along the course of the study into account. No corresponding prediction 13 
of favorable response to a DASH-only intervention was possible. Thus, we demonstrate the 14 
practical utility of a machine learning analysis pipeline for predicting BP benefit of fasting in 15 
MetS patients with hypertension. Personalized nutrition, informed by -omics measurements, is 16 
therefore a possible translational benefit of our study.  17 
 18 
Limitations 19 
It is important to recognize that our study represents patients with hypertension and MetS solely 20 
from a Caucasian-European background. This selection criterion introduces a selection bias in 21 
our study design. Additional research is necessary to elucidate whether the results presented 22 
here could be generalizable to a more heterogenous patient population. Further, our recruitment 23 
procedure could already have introduced a selection bias toward patients who were interested 24 
in fasting/dietary studies and therefore are sensitive about their cardiometabolic health. Since 25 
the participants were especially interested in the fasting procedure, the allocated DASH 26 
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participants were offered after successful completion of the study a cost-free fasting cycle. 1 
However, we cannot exclude that this led to an increased long-term motivation compared to the 2 
participants, who started with the fasting protocol. In addition, the relatively low patient number 3 
could be regarded as a limitation. Although our present study is large enough to allow inference 4 
of significance for most strong contributors to the observed effect, results are likely not 5 
complete, and follow-up in additional and larger studies will be needed for a comprehensive 6 
view of subtle fasting-associated host and microbiome features. Our study design did not allow 7 
to blind participants regarding their intervention. To maximally reduce the bias, the scientific 8 
staff were blinded during the process of processing and analyses of collected samples and 9 
measurements. Further, the present study cannot infer how frequently fasting cycles should be 10 
repeated to control BP in at-risk patients, nor whether it is as effective without a concomitant 11 
DASH intervention. Future clinical studies are needed to test these hypotheses. 12 
 13 
Conclusions 14 
Our data demonstrates that fasting induces changes to gut microbiome and immune homeostasis 15 
with a sustained beneficial effect on body weight and BP. The favorable impact of fasting 16 
shown here highlights this intervention as a promising non-pharmacological intervention for 17 
the treatment of MetS. 18 
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Tables 1 
Table 1. Patient characteristics at baseline. 2 
 FASTING 
+ DASH 
DASH 
Females/Males 23/12 21/15 
Age (year) 58 ± 8 62 ± 8 
Height (cm) 171 ± 8 171 ± 9 
Office SBP (mm Hg) 136 ± 15 138 ± 16 
Office DBP (mm Hg) 88 ± 11 88 ± 9 
24h ABPM SBP (mm Hg) 132 ± 9 131 ± 9 
24h ABPM DBP (mm Hg) 81 ± 8 81.4 ± 7 
24h ABPM MAD (mm Hg) 104 ± 8 104 ± 7 
24h ABPM peripheral resistance (mm Hg*s/ml) 1.4 ± 0.1 1.3 ± 0.1 
SBP day (mm Hg) 134 ± 10 133 ± 10 
DBP day (mm Hg) 83 ± 9 84 ± 7 
SBP nocturnal (mm Hg) 120 ± 12 121 ± 10 
DBP nocturnal (mm Hg) 71.5 ± 8 71.6 ± 7 
Weight (kg) 99 ± 17 96 ± 17 
BMI (kg/m2) 34 ± 4.9 33 ± 4.7 
Hip circumference (cm) 115 ± 20 113 ± 17 
Waist circumference (cm) 116 ± 11 114 ± 12 
Waist to hip ratio 1.1 ± 0.7 1.0 ± 0.2 
Body fat ratio (%) 42 ± 8 39 ± 10 
HOMA-index 2.8 ± 2.1 3.4 ± 2.4 
Insulin (mU/l) 10.4 ± 6.4 12.1 ± 7.4 
Plasma glucose (mg/dl) 105 ± 20 110 ± 20 
Hb-A1C (%) 5.8 ± 0.4 5.9 ± 0.7 
Hb-A1C IFCC (mmol/mol) 39.6 ± 4.8 41.2 ± 7.4 
Triglyceride (mg/dl) 166 ± 106 169 ± 109 
Cholesterol (mg/dl) 220 ± 48 222 ± 54 
HDL (mg/dl) 50 ± 11 51 ± 10 
LDL(mg/dl) 137 ± 36 140 ± 45 
LDL/HDL ratio 2.8 ± 0.7 2.8 ± 0.9 
CRP (mg/l) 0.4 ± 0.4 0.3 ± 0.3 
IL-6 (pg/ml) 3.1 ± 2.0 2.8 ± 2.2 
Creatinine (mg/dl) 0.9 ± 0.2 0.9 ± 0.2 
eGFR Cockroft-Gault (ml/min) 120 ± 39 107 ± 32 
  3 
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Figures and Figure Legends 1 
Fig. 1. Fasting has pervasive host and microbiome impact. (A) Study design is shown. 2 
Subjects are followed from baseline (V1), randomly assigned to begin a modified DASH diet 3 
only or to undergo a five-day fast followed by a modified DASH diet. Follow-up is done at one 4 
week (V2) and three months (V3). (B) Fasting has no significant (MWU P>0.05) impact on gut 5 
microbiome alpha diversity (Shannon diversity from mOTUv2 OTUs) across observation times 6 
V1-V3. (C) Fasting has no significant (MWU P>0.05) impact on gut microbiome beta diversity 7 
(Bray-Curtis dissimilarity from mOTUv2 OTUs, shown are all between-donor comparisons per 8 
time point) across observation times V1-V3. (D) Fasting significantly shifts the gut microbiome 9 
towards a characteristic compositional state, while refeeding reverses this change. 10 
Unconstrained Principal Coordinates graph with first two dimensions shown. Axes show Bray-11 
Curtis dissimilarities of rarefied mOTUv2 OTUs between samples; each participant in the 12 
fasting arm is shown as two lines, one red (fasting change), one blue (refeeding change) 13 
connected (centered) at the origin for ease of visualization. Axes show fasting and refeeding 14 
deltas after one-week intervention and three-month refeeding. Pseudonym participant ID 15 
numbers are shown on the point markers. Transparent circle markers show arithmetic mean 16 
position of fasting and recovery deltas respectively. PERMANOVA test P-values reveal 17 
significant dissimilarity (P<0.05) between samples from each visit V1-V3 in the original 18 
distance space, stratifying by donor. (E) Fasting significantly shifts the host immune cell 19 
population towards a characteristic state, while refeeding reverses it. Same as in (D) but using 20 
Euclidean distances. (F) Gut microbial taxa significantly enriched/depleted upon 21 
fasting/refeeding. Taxa (mOTUv2 OTUs) are shown on the vertical axis, and effect sizes 22 
(Cliff’s delta) shown on the horizontal axis. Red arrows represent fasting effects (V2-V1 23 
comparison), blue arrows refeeding effects (V3-V2 comparison). Bold arrows are significant 24 
(nested model comparison of a linear model for rarefied abundance of each taxon, comparing a 25 
model incorporating patient ID, age, sex and all dosages of relevant medications) to a model 26 
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additionally incorporating time point, requiring likelihood test Benjamini-Hochberg corrected 1 
FDR<0.1 and additionally pairwise post hoc MWU test P<0.05). (G) Gut microbial gene 2 
functional modules (KEGG and GMM models analysed together) significantly 3 
enriched/depleted upon fasting/refeeding. (H) General immune cell populations significantly 4 
enriched/depleted upon fasting/refeeding. (I) Specific immune cell subpopulations. (G-I) Same 5 
test as in (F), subset of altered features shown for clarity. 6 
 7 
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Fig. 2. Fasting effects are distinct from those of a modified DASH diet only, and connected 1 
to vascular health benefits. (A) Fasting followed by a modified DASH diet, but not a DASH 2 
diet alone, significantly (MWU P < 0.05) improves 24h ambulatory SBP and MAP three months 3 
post intervention. Lines show individual participant trajectories. (B) MetS subjects beginning a 4 
modified DASH diet post fasting significantly reduce their intake of antihypertensive 5 
medication by three months post intervention, compared to subjects beginning a DASH diet 6 
only. 2 P=0.035. (C) Changes in 24h ambulatory SBP in responders and non-responders 7 
including change in antihypertensive medication. (D, E) One week of fasting followed by 8 
modified DASH diet, but not DASH diet alone, caused significant (MWU P<0.05) BMI and 9 
body weight reduction in MetS patients, persisting three months later. (F) Comparison of 10 
changes in 24h ambulatory SBP and body weight, respectively between baseline and followup 11 
in both study arms. Each dot represents an individual. (G) Body weight change is not 12 
significantly different between responders and non-responders in the fasting arm between 13 
baseline and followup. (H) Selected cardiometabolic risk parameters (vertical axis) altered in 14 
the fasting arm compared to the DASH arm. Heatmap hues show Cliff’s delta signed effect 15 
sizes, with asterisk indicating post hoc univariate significance after compensating for drug 16 
dosage changes (see Methods). Horizontal axis shows each time point comparison: change 17 
during fasting/week three of DASH, change during refeeding/three months of DASH, and 18 
change during the study period as a whole. (I) A majority of host and microbiome effects 19 
reported from the DASH+fasting arm do not replicate under DASH only. Comparative effect 20 
size plot contrasting features altered significantly only under DASH+fasting (coloured markers, 21 
N=275) with features altered significantly also under DASH alone, or with absolute effect size 22 
greater in DASH alone (gray markers, N=133). For the former category, colour hue shows 23 
direction of effect, colour intensity scope of effect, and marker shape which time point 24 
comparison is shown. Vertical axis shows effect size in DASH only, horizontal effect size in 25 
DASH+fasting. Selected features are named for reference. 26 
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Fig. 3. Subjects responding favorably to fasting exhibit stronger changes in commensal 1 
abundance under intervention. (A) Cuneiform plot shows subset of bacterial taxa, at different 2 
taxonomic levels and measured either using 16S sequencing or shotgun sequencing, altered 3 
significantly (drug-adjusted post hoc FDR<0.05) in abundance tested in intervention responders 4 
only (vertical axis). Signed effect size are shown through marker direction and color, hue and 5 
size represent absolute effect size. Solid borders indicate significance. Markers not shown could 6 
not be tested in the DASH arm as shotgun data was unavailable, or showed no difference in 7 
rank-transformed values (Cliff’s delta=0). Horizontal axis separates tests for fasting 8 
(comparison of baseline to after one week), recovery (comparison of after one week to three 9 
months), and study effect (comparison of baseline to three-month follow-up). DASH results are 10 
from the DASH arm only, responders are tests using only the responders (as per decision tree) 11 
in the fasting arm. (B) Same view as (A) but with regards to gut functional modules (selected 12 
subset shown for clarity). (C) Same view as (A) but with regards to immune cell subpopulations 13 
(selected subset of GMMs shown for clarity). Treg: FoxP3
+ cells, MAIT: V7.2+CD161+CD4-14 
CD3+. 15 
 16 
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Fig. 4. Blood pressure-microbe-immune association. (A) Chord diagram visualises the 1 
interrelation between BP (24h ambulatory systolic, mean or diastolic BP) and fasting-impacted 2 
microbiome functional or taxonomic features, and immune cell subsets. Features are shown that 3 
form triplets of immune, microbial and phenotype variables where at least two of three 4 
correlations are significant (Spearman FDR < 0.05, post hoc nested model test accounting for 5 
same-donor samples < 0.05) in the fasting arm of our novel cohort, and where in addition one 6 
or more feature significantly (drug-adjusted post hoc FDR < 0.05) are affected by the 7 
intervention. Colour of the connectors indicates positive or negative association (Spearman´s 8 
rho), colour of the cells within the tracks indicates changes upon fasting, refeeding and study 9 
effect (Cliff´s delta, white if not significant), respectively. (B) Cumulative absolute number and 10 
relative abundance of circulating IFN+TNF+, IL-2-TNF+ and IL-2+TNF+ mucosa-11 
associated invariant T cells (MAIT) cells within the fasting arm subdivided by BP-12 
responsiveness (median, n=30 for all, n=20 for responders, n=8 for non-responders, 13 
respectively). (C) Absolute number of circulating IL-2+TNF+ (All: P = 0.019, Responder: P = 14 
0.024), TNF+ (All: P = 0.006; Responder: P = 0.022) and IFN+ (All: P = 0.001; Responder:  15 
=0.007) MAIT cells within the fasting arm subdivided by BP-responsiveness (n-number as in 16 
(B); MWU test after Benjamini-Hochberg correction). (D) Hierarchical clustering of 17 
microbiome features-associated immune features. Colour indicates Spearman´s rho. (E) 18 
Correlations of circulating IL-2+TNF+, TNF+ and IFN+ MAIT cells and 24h ambulatory 19 
SBP (*FDR-corrected P=0.044, 0.022 and 0.022, respectively). (F) Correlations of circulating 20 
non-classical CD14lowCD16++HLA-DR+ monocytes and 24h ambulatory MAP in responder 21 
(*FDR-corrected P=0.002).  (G) Correlations of circulating GM-CSF+IL-2-IL-17- of % CD3+ 22 
and 24h ambulatory SBP (*FDR-corrected P=0.047). n-number for (C-G) as in (B). MAIT: 23 
V7.2+CD161+CD4-CD3+. 24 
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Fig. 5. Long-lasting BP-responders and non-responders differ in microbiome and 1 
immunome composition. (A) Features altered at baseline in responders vs. non-responders and 2 
altered during intervention in responders. Effect size (Cliff’s delta) is shown comparing 3 
responders and non-responders. Transparency indicates non-significant differences (drug-4 
adjusted post hoc FDR0.05). (B) Prediction model weights for blood pressure response using 5 
the immunome dataset at baseline. The top ten immunome features were used to build a 6 
multivariate logistic-regression algorithm. Single-subject prediction was quantified using a 7 
leave-one-out cross-validation procedure. The bar plots represent the regression in a model with 8 
binary output (responder yes=1 vs no=0) for every feature. (C) Quantification of the immunome 9 
features at baseline used in the prediction model to predict BP response in the future, split into 10 
responders and non-responders. MAIT: V7.2+CD161+CD4-CD3+. 11 
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